TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33693537
Drug: Standard-of-care control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care control (PO-10, rifampicin 10 mg/kg/day)
Study: 33693537
Drug: Intravenous rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rifampicin (IV-20, 20 mg/kg/day)
Study: 33693537
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral rifampicin (PO-35, 35 mg/kg/day)
Study: 33549194
Drug: Posaconazole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (300 mg twice on day 1, followed by 300 mg once a day for days 2–84)
Study: 33549194
Drug: Voriconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2–84)
Study: 34488846
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg PZQ at baseline and placebo at 6 months
Study: 34488846
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg PZQ at baseline and 40 mg/kg PZQ at 6 months
Study: 34488846
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg PZQ at baseline and placebo at 6 months
Study: 34488846
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg PZQ at baseline and 80 mg/kg PZQ at 6 months
Study: 33369355
Drug: CC-486 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300 mg) once daily for 14 days per 28-day cycle
Study: 33369355
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 14 days per 28-day cycle
Study: 35183780
Drug: 0.12% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% CHX solutions
Study: 32750572
Drug: Daily symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily symptom check-in text messages, plus medication reminder or inspirational quote text
Study: 35795313
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 900 mg twice daily for 3 months
Study: 33721560
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg IV every 3 weeks for 16 cycles or up to 1 year
Study: 34622679
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with cilostazol and clopidogrel or aspirin
Study: 34622679
Drug: SAPT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAPT with clopidogrel or aspirin
Study: 32293706
Drug: Pitolisant hydrochloride
Normalized name: PITOLISANT HYDROCHLORIDE
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pitolisant hydrochloride (40 mg)
Study: 32745891
Drug: Oxytocin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (both doses)
Study: 37277072
Drug: Dexpramipexole 150
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole 150 mg BID
Study: 37277072
Drug: Dexpramipexole 75
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole 75 mg BID
Study: 34836388
Drug: Biobran/MGN-3 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobran/MGN-3 (500 mg/day)
Study: 33517607
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen treatment (venturi mask/nasal cannula)
Study: 33264183
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor therapy
Study: 36288939
Drug: Ciclesonide 400
Normalized name: Ciclesonide 400 microgram and formoterol fumarate dihydrate 12 microgram and tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 400 µg three times a day for seven days
Study: 35436957
Drug: Intensive education
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive education program on treatment of tobacco-use disorder
Study: 33030598
Drug: Supervised aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised aerobic endurance, resistance, and balance exercises twice a week at the hospital plus home-based exercise once a week for 12-24 weeks
Study: 32362552
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bevacizumab (subgroup with BCVA ≤69 letters)
Study: 32362552
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab (subgroup with BCVA ≤69 letters)
Study: 32362552
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bevacizumab (subgroup with BCVA ≥70 letters)
Study: 32362552
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab (subgroup with BCVA ≥70 letters)
Study: 33668564
Drug: EGF-containing ointment
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF-containing ointment
Study: 36154487
Drug: Dramatic narrative
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dramatic narrative featuring Latina characters countering prevalent myths about COVID-19 vaccines
Study: 36301511
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (5 mg/kg second dose)
Study: 36301511
Drug: Enteral caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral caffeine (5 mg/kg second dose)
Study: 35565828
Drug: Mg-Teadiola (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-Teadiola (combination of magnesium, vitamins B6, B9, B12, rhodiola, and green tea/L-theanine)
Study: 35565828
Drug: Mg-Teadiola
Normalized name: MG 217 Psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-Teadiola
Study: 38743075
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (control)
Study: 32022261
Drug: APG-157 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-157 (100 mg or 200 mg, delivered transorally every hour for 3 hours)
Study: 34112734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eosinophils and FENO
Study: 34483640
Drug: Lowest postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowest postoperative pre-albumin < 15 mg/dL
Study: 33050362
Drug: HBOT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOT treatment after exercise in NN conditions (HNN group)
Study: 33050362
Drug: HBOT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOT treatment after exercise in HH conditions (HHH group)
Study: 616871163
Drug: Moderate aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate aerobic exercise (at least 30 min per day, 5 times weekly)
Study: 34340880
Drug: 0.75% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% citric acid spray
Study: 34340880
Drug: Cool water
Normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 15 g in 100 g TOPICAL STICK [Secret Cool Waterlily Invisible]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cool water spray
Study: 35220330
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) pregabalin (150 to 600 mg/d) once daily for 12 weeks
Study: 35220330
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) pregabalin (150 to 600 mg/d) twice daily for 12 weeks
Study: 35220330
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) pregabalin
Study: 32059724
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living abilities of the PwD
Study: 34226214
Drug: Enhanced occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced occupational therapy discharge planning intervention (the HOME programme) including pre and postdischarge home visits, goal setting, and occupational therapy in the home.
Study: 35370039
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of adjuvant doublet chemotherapy (CAPOX)
Study: 35370039
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of adjuvant doublet chemotherapy
Study: 33336381
Drug: Bumetanide (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (diuretic agent)
Study: 34623899
Drug: Ifosfamide and
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide and doxorubicin chemotherapy plus 55.8 Gy RT (Arm C)
Study: 35510727
Drug: Epilepsy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epilepsy group using psychiatric drugs
Study: 35752301
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with misoprostol (800 μg sublingually)
Study: 33726819
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents
Study: 36414990
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by 4 interforaminal implants (Test)
Study: 36414990
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by 2 interforaminal implants (Control)
Study: 32389326
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) 600 mg BID for 14 days under fed conditions
Study: 32389326
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) 800 mg BID for 14 days under fed conditions
Study: 32389326
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) 800 mg BID for 7-14 days under fed conditions
Study: 33896930
Drug: Paclitaxel drug-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-coated balloons (Pantera Lux)
Study: 34175866
Drug: Closed‐incision negative‐pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed‐incision negative‐pressure therapy (ciNPT)
Study: 33792788
Drug: Ranibizumab (RBZ)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (RBZ) therapy, 0.5 or 2.0 mg, monthly intravitreal injections for 6 consecutive injections followed by as-needed treatments.
Study: 33709192
Drug: Dexmedetomidine-soaked nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-soaked nasal packing (1 μg kg−1)
Study: 33709192
Drug: Dexmedetomidine-soaked nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-soaked nasal packing (2 μg kg−1)
Study: 33709192
Drug: Dexmedetomidine-soaked nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-soaked nasal packing (4 μg kg−1)
Study: 36327043
Drug: SC‐R group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC‐R group (n=29) - 24 weeks of no cost Nicotine Replacement Treatment (NRT)
Study: 36327043
Drug: SC + group (n=32)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC + group (n=32) - 24 weeks of no cost NRT plus two initial individual counselling sessions of motivational interviewing and weekly psychosocial group support for 24 weeks
Study: 32109729
Drug: Skills preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skills preparation group
Study: 32109729
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) group
Study: 33831949
Drug: Antioxidant cocktail
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant cocktail (741 mg/d polyphenols, 2.1 g/d omega-3 fatty acids, 168 mg/d vitamin E, and 80 μg/d selenium)
Study: 34791283
Drug: PP6M (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP6M (700 or 1000 mg eq.)
Study: 34791283
Drug: PP3M (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP3M (350 or 525 mg eq.)
Study: 32004582
Drug: Ultrahypofractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrahypofractionated radiation therapy (UHF) - 7 × 6.1 Gy, 2.5 weeks
Study: 32004582
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiation therapy (CF) - 39 × 2.0 Gy, 8 weeks
Study: 34554831
Drug: Acid-oxidising solution
Normalized name: salicylic acid / zinc oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-oxidising solution (AOS)
Study: 32217557
Drug: SFX-01 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFX-01 (300 mg)
Study: 35963416
Drug: R. damascena
Approvals — FDA: no, EMA: no, PMDA: no
Description: R. damascena and brown sugar syrup (0.1 g R. damascena petals mixed with 0.85 g brown sugar per 1 mL)
Study: 35963416
Drug: R. damascena
Approvals — FDA: no, EMA: no, PMDA: no
Description: R. damascena and brown sugar syrup
Study: 36151947
Drug: Needle flexor
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle flexor tendon tenotomy treatment
Study: 36151947
Drug: Standard nonsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nonsurgical treatment alone
Study: 32493720
Drug: HIV Env
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV Env subunit vaccine
Study: 38529674
Drug: Deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg QD
Study: 32713104
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (HDDT) with rabeprazole 20 mg q.i.d. and amoxicillin 1 g q.i.d. for 14 days
Study: 32713104
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (STT) with rabeprazole 20 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. for 14 days
Study: 32246662
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem ointment
Study: 35020928
Drug: Concurrent viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent viral features and radiographic pneumonia
Study: 33289822
Drug: Co-trimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (960 mg orally twice daily)
Study: 34228547
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic agents
Study: 33400412
Drug: VP-102 (0.7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP-102 (0.7% w/v cantharidin) applied topically every 21 days for a maximum of 4 treatments.
Study: 36316921
Drug: Levocarnitine oral
Normalized name: levocarnitine Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine oral solution
Study: 32234700
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) app used for 6 weeks
Study: 35020023
Drug: Epsilon-aminocaproic acid
Normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon-aminocaproic acid (EACA) 20 ml of 5% solution
Study: 35020023
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control) 20 ml
Study: 33757437
Drug: Cinacalcet alongside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet alongside standard therapy
Study: 33534264
Drug: Physostigmine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.02 mg/kg bolus followed by 0.01 mg/kg/hour for 24 hours)
Study: 32535711
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2) plus Oxaliplatin (100 mg/m2) every 2 weeks
Study: 32720608
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg IV daily for at least 7 days)
Study: 32320006
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1000 mg/d for 6 weeks
Study: 32698144
Drug: Genetically instrumented
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically instrumented TSH (approximately 0.8 mIU/L)
Study: 33565893
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus oral antidepressant (ESK + oral AD)
Study: 33565893
Drug: Oral antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidepressant plus nasal placebo (oral AD + PBO)
Study: 33823606
Drug: Dual-therapy sirolimus-eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS)
Study: 36178946
Drug: Real US-guided
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real US-guided dry needling with exercise therapy (G1)
Study: 36178946
Drug: Placebo US-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo US-guided dry needling with exercise therapy (G2)
Study: 36178946
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy solely (G3)
Study: 32169925
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (CL) insulin delivery for 24 months
Study: 32169925
Drug: Standard multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multiple daily injections (MDI) therapy for 24 months
Study: 36450940
Drug: 200-mg testosterone
Normalized name: testosterone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg testosterone enanthate/wk (TEST)
Study: 35713950
Drug: Progesterone 200
Normalized name: progesterone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 200 mg daily
Study: 34435933
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of tetravalent measles-mumps-rubella-varicella vaccine (V2 group)
Study: 34435933
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose trivalent measles-mumps-rubella (MMR) vaccine and one dose of varicella vaccine (V1 group)
Study: 34435933
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MMR vaccine (V0 group, control)
Study: 33827700
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment (0.25 mcg/day for 4 months)
Study: 33827700
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment (0.25 mcg/day for 4 months) in patients with Ff genotype
Study: 34007434
Drug: Operating room
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operating room nursing intervention combined with traditional treatment methods
Study: 34007434
Drug: Traditional nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional nursing combined with traditional treatment
Study: 34463805
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia group (spinal fentanyl followed by oral tramadol, paracetamol, and diclofenac every 6 hours for 48 hours)
Study: 34463805
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine group (spinal morphine followed by oral tramadol, paracetamol, and diclofenac)
Study: 33020005
Drug: 6 educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 educational sessions, parent feedback via the Communication Assessment Tool (CAT), monthly communication tips
Study: 34197699
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication therapy monitoring and management via a smartphone-enabled mHealth app
Study: 34821175
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (cisplatin with pemetrexed)
Study: 34821175
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (cisplatin with pemetrexed)
Study: 34895064
Drug: Mindfulness-Based Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive-Behavioral Sex Therapy (MBCST)
Study: 35817672
Drug: Bivalirudin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (1 mg/kg bolus followed by 2.5 mg/kg/h infusion, adjusted to maintain ACT >480 s)
Study: 35817672
Drug: Bivalirudin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (1 mg/kg bolus followed by 2.2 ± 0.4 mg/kg/h infusion)
Study: 32151792
Drug: Illusory patterns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illusory patterns with vertically aligned white dots in L shape
Study: 32151792
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of T shape vs L shape configurations
Study: 32428786
Drug: Exercise training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training, nutritional education, and medication reconciliation for 5.1 ± 0.6 months
Study: 35616942
Drug: Spermidine supplementation
Normalized name: spermidine
DrugBank: Spermidine (DB03566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermidine supplementation (0.9 mg spermidine/d) for 12 months
Study: 33564824
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (800 µg daily for 3 years)
Study: 35173154
Drug: amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin + cefotaxime